Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or
“Novo”), pioneering a holistic approach to patient-first health and
wellness through a multidisciplinary healthcare ecosystem of
services and product innovation, has signed a Membership Interest
Purchase Agreement (“MIPA”) to acquire Clinical Consultants
International LLC (“CCI”) in an all-stock transaction (the
“Transaction”). The transaction is expected to close no later than
April 15, 2022.
Established in 2006 and led by Dr. Joseph M. Chalil, MD, MBA,
FACHE and Chairman of Novo’s Medical Advisory Board, CCI is a
global consulting firm specializing in providing value-added
services for the pharmaceutical, biotech, healthcare management,
hospital management, medical marketing and strategic planning,
health policy, and medical device sectors. CCI has a portfolio of
leading multi-national healthcare clients, assisting each through
clinical and regulatory development as well as entrance into new
markets. Upon closing of the Transaction, Dr. Chalil will continue
his leadership of CCI.
One of CCI’s clients is Boditech Med, a South Korea based
in-vitro diagnostics company founded in 1998, which sells more than
90 biomarker products, including capillary blood, venous blood, and
plasma testing, in 120 countries. In coordination with CCI,
Boditech recently announced its planned expansion of operations to
Florida with a manufacturing site intended to employ hundreds of
Americans while also pursuing opportunities in other states, along
with a partnership in Canada.
Robert Mattacchione, Novo’s CEO and Board Chairman, commented,
“Under the leadership of Dr. Chalil, CCI has built a stellar
reputation as a strong strategic partner for global companies
evaluating entry into North American markets. We believe that
bringing CCI into the Novo ecosystem will allow each of our
respective firms to mutually benefit from the wide product and
service offerings we now have available for multi-national
companies operating in the healthcare industry. The proposed
acquisition marks a significant milestone for Novo and CCI to
collectively create a voice of significance in the healthcare
industry.”
Dr. Chalil stated, “Since 2006, our team at CCI has established
a great reputation and long-lasting client relationships globally.
Much of our client base is eagerly evaluating processes to enter
the North American market. Integrating with the Novo team is
expected to provide our clients a more efficient manner in which to
enter the U.S. and Canada through the multidisciplinary healthcare
ecosystem Novo continues to build.”
Dr. Chalil is an author of several scientific and research
papers in international publications. He is also the Chairman of
the Complex Health Systems Advisory Board, H. Wayne Huizenga
College of Business and Entrepreneurship at Nova Southeastern
University in Florida, and a member of Dr. Kiran C. Patel College
of Allopathic Medicine Executive Leadership Council. A veteran of
the U.S. Navy Medical Corps, he is board certified in healthcare
management. He has been awarded a Fellowship by the American
College of Healthcare Executives, an international professional
society of more than 40,000 healthcare executives who lead
hospitals, healthcare systems and other healthcare organizations.
Additionally, Dr. Chalil is the former Chairman of the
Indo-American Press Club. He is an expert in U.S. healthcare policy
and a strong advocate for patient-centered care. A strong proponent
of providing healthcare access to everyone, Dr. Chalil’s new book,
Beyond the COVID-19 Pandemic: Envisioning a Better World by
Transforming the Future of Healthcare, is on Amazon’s Best Sellers
List.
About Novo Integrated Sciences,
Inc.
Novo Integrated Sciences, Inc. is pioneering a holistic approach
to patient-first health and wellness through a multidisciplinary
healthcare ecosystem of multiple patient and consumer touchpoints
for services and product innovation. Novo offers an essential and
differentiated solution to deliver, or intend to deliver, these
services and products through the integration of medical
technology, advanced therapeutics, and rehabilitative science.
We believe that “decentralizing” healthcare, through the
integration of medical technology and interconnectivity, is an
essential solution to the rapidly evolving fundamental
transformation of how non-catastrophic healthcare is delivered both
now and in the future. Specific to non-critical care, ongoing
advancements in both medical technology and inter-connectivity are
allowing for a shift of the patient/practitioner relationship to
the patient’s home and away from on-site visits to primary medical
centers with mass-services. This acceleration of “ease-of-access”
in the patient/practitioner interaction for non-critical care
diagnosis and subsequent treatment minimizes the degradation of
non-critical health conditions to critical conditions as well as
allowing for more cost-effective healthcare distribution.
The Company’s decentralized healthcare business model is
centered on three primary pillars to best support the
transformation of non-catastrophic healthcare delivery to patients
and consumers:
- First Pillar: Service Networks. Deliver multidisciplinary
primary care services through (i) an affiliate network of clinic
facilities, (ii) small and micro footprint sized clinic facilities
primarily located within the footprint of box-store commercial
enterprises, (iii) clinic facilities operated through a franchise
relationship with the Company, and (iv) corporate operated clinic
facilities.
- Second Pillar: Technology. Develop, deploy, and integrate
sophisticated interconnected technology, interfacing the patient to
the healthcare practitioner thus expanding the reach and
availability of the Company’s services, beyond the traditional
clinic location, to geographic areas not readily providing
advanced, peripheral based healthcare services, including the
patient’s home.
- Third Pillar: Products. Develop and distribute effective,
personalized health and wellness product solutions allowing for the
customization of patient preventative care remedies and ultimately
a healthier population. The Company’s science-first approach to
product innovation further emphasizes our mandate to create and
provide over-the-counter preventative and maintenance care
solutions.
Innovation through science combined with the integration of
sophisticated, secure technology assures Novo Integrated Sciences
of continued cutting-edge advancement in patient first
platforms.
For more information concerning Novo Integrated Sciences, please
visit www.novointegrated.com. For more information on Novo
Healthnet Limited, Novo’s wholly owned subsidiary, please visit
www.novohealthnet.com.
Twitter, LinkedIn, Facebook, Instagram, YouTube
Forward-Looking
Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. All statements other than statements of historical facts
included in this press release are forward-looking statements. In
some cases, forward-looking statements can be identified by words
such as "believe," “intend,” "expect," "anticipate," "plan,"
"potential," "continue" or similar expressions. Such
forward-looking statements include risks and uncertainties, and
there are important factors that could cause actual results to
differ materially from those expressed or implied by such
forward-looking statements. These factors, risks and uncertainties
are discussed in Novo’s filings with the Securities and Exchange
Commission. Investors should not place any undue reliance on
forward-looking statements since they involve known and unknown,
uncertainties and other factors which are, in some cases, beyond
Novo’s control which could, and likely will, materially affect
actual results, levels of activity, performance or achievements.
Any forward-looking statement reflects Novo’s current views with
respect to future events and is subject to these and other risks,
uncertainties and assumptions relating to operations, results of
operations, growth strategy and liquidity. Novo assumes no
obligation to publicly update or revise these forward-looking
statements for any reason, or to update the reasons actual results
could differ materially from those anticipated in these
forward-looking statements, even if new information becomes
available in the future. The contents of any website referenced in
this press release are not incorporated by reference herein.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220323005295/en/
Chris David, COO-President Novo Integrated Sciences, Inc.
chris.david@novointegrated.com (888) 512-1195
Novo Integrated Sciences (NASDAQ:NVOS)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Novo Integrated Sciences (NASDAQ:NVOS)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024